Overall Survival and Treatment-Related Mortality
The median duration of follow-up for surviving patients was 2.9 years
(IQR 1.3-4.8) years. Death occurred in 100 (29.1%) patients, with 60
dying from the primary disease, 36 from a complication, and four from
another/unknown cause. Of patients who died post-HSCT, the median days
from HSCT to death was 264 (IQR 135-500).
The relationship between glucose CV and risk of death was dependent on
HSCT type (p=0.079 pre-HSCT and p=0.024 post-HSCT). After adjusting for
post-HSCT steroids and GVHD, doubling of day 0-30 glucose CV was
associated with a 1.38 (95% CI: 0.996-1.91 p=0.053) fold increased risk
of death among allogeneic HSCT patients, versus a 0.75 (95% CI:
0.48-1.15; p=0.18) fold increased risk among autologous HSCT patients
(Table 3, Figure 2). Glucose CV was not associated with
treatment-related mortality (TRM) (Table 3, Figure 2).